Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: A matched-pair analysis

Oncology

Volumn 73, Issue 5-6, 2008, Pages 328-334

  Tougeron, David ^a   Di Fiore, Frédéric ^a   Hamidou, Hadji ^b   Rigal, Olivier ^b   Paillot, Bernard ^a   Michel, Pierre ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b CRLCC Henri Becquerel   (France)

Author keywords

Definitive chemoradiotherapy; Oesophageal cancer

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; FLUOROURACIL; IRINOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEGLUTITION DISORDERS; ESOPHAGEAL NEOPLASMS; FEMALE; FRANCE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 45549106473     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000134476     Document Type: Article

References (29)

1. Blot WJ, Mc Laughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
2. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003;349:2241-2252.
3. Benhamiche AM, Colonna M, Aptel I, Launoy G, Schaffer P, Arveux P, Buemi A, Dubreuil A, Daures JP, Faivre J: Estimation of the incidence of digestive tract cancers by region. Gastroenterol Clin Biol 1999;23:1040-1047.
4. Launoy G, Milan CH, Faivre J, Pienkowski P, Milan CI, Gignoux M: Alcohol, tobacco and oesophageal cancer: effects of the duration of consumption, mean intake and current and former consumption. Br J Cancer 1997;75:1389-1396.
5. Kleinberg L, Forastiere AA: Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:4110-4117.
6. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317.
7. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-1168.
8. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials Group: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-234.
9. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, Vaporciyan AA, Rice DC, Fukami N, Roth JA, Ajani JA: Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer 2005;36:69-76.
10. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, Trans-Tasman Radiation Oncology Group, Australasian Gastro-Intestinal Trials Group: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the esophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659-668.
11. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005;104:2365-2372.
12. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE: Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 patterns of care study. J Clin Oncol 2000;18:455-462.
13. Polee MB, Hop WCJ, Kok TC, Eskens FALM, Van der Burg MEL, Splinter TA, Siersema PD, Tilanus HW, Stoter G, van der Gaast A: Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 2003;89:2045-2050.
14. Di Fiore F, Lecleire S, Rigal O, Galais MP, Ben Soussan E, David I, Paillot B, Jacob JH, Michel P: Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006;12:4185-4190.
15. Atkinson M: Diseases of the alimentary system. Dysphagia. Br Med J 1977;1:91-93.
16. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598.
17. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the oesophagus. N Engl J Med 1997;337:161-167.
18. Tio TL, Coene PP, Den Hartog Jager FC, Tytgat GN: Preoperative TNM classification of esophageal carcinoma by endosonography. Hepatogastroenterology 1990;37:376-381.
19. Michel P, Adenis A, Fiore FD, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH, Hellot MF, Prod'homme S, Paillot B: Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer 2006;95:705-709.
20. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, Ajani JA: Histologic types as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 2006;106:552-558.
21. Kusumoto T, Sakaguchi Y, Maehara Y, Nakashima T, Furusawa M, Sugimachi K: Comparison of in vitro anticancer chemosensitivity between human squamous cell carcinoma and adenocarcinoma. Oncology 1992;49:343-346.
22. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK: Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996;14:503-513.
23. Osoba D, Rusthoven JJ, Turnbull KA, Evans WK, Shepherd FA: Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer. J Clin Oncol 1985;3:1478-1485.
24. Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotte P, Lerebours E, Michel P: Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007;102:2557-2563.
25. Geh JI, Crellin AM, Glynne-Jones R: Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001;88:338-356.
26. Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M, Hickish T: Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 2006;42:827-834.
27. Van Groeningen C, Richel D, Giaccone G: Gefitinib phase II study in second-line treatment of advanced esophageal cancer. J Clin Oncol 2004;22(suppl 14):4022.
28. Shah MA, Ramanathan RK, Ilson DH, Randazzo J, Schwartz GK, Tse A, D'Adamo D, Levner A, Capanu M, Kelsen DP: Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal (GEJ) adenocarcinoma. J Clin Oncol 2006;24(suppl 18):4020.
29. Ott K, Weber W, Siewert JR: The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 2006;19:433-442.